Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates

Transplantation

Volumn 79, Issue 7, 2005, Pages 791-801

  Borie, Dominic C ^a   Changelian, Paul S ^b   Larson, Michael J ^a   Si, Ming Sing ^a   Paniagua, Ricardo ^a   Higgins, John P ^c   Holm, Bari ^a   Campbell, Andrew ^a   Lau, Macy ^a   Zhang, Sally ^a   Flores, Mona G ^a   Rousvoal, Geraldine ^a   Hawkins, Jennifer ^a   Ball, Douglas A ^b   Kudlacz, Elizabeth M ^b   Brissette, William H ^b   Elliott, Eileen A ^b   Reitz, Bruce A ^a   Morris, Randall E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CP690,550; Immunosuppression; JAK STAT; JAK3; Primates; Transplantation

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; CALCIUM CARBONATE; JANUS KINASE 3;

ANEMIA; ANIMAL CELL; ARTERIAL PRESSURE; ARTICLE; BIOPSY; CALCIUM URINE LEVEL; CONTROLLED STUDY; FLUID INTAKE; GLUCOSE BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MONKEY; NATURAL KILLER CELL; NEPHRITIS; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; URINE VOLUME;

ADMINISTRATION, ORAL; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASE 3; KIDNEY; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LYMPHOCYTES; MACACA FASCICULARIS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 20244368823     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000157117.30290.6F     Document Type: Article

References (59)

1. Hariharan S. Case 4: cardiovascular risk in renal transplantation. Transplantation 2003; 75: 1610.
2. Ojo AO, Hanson JA, Wolfe RA, et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307.
3. Serkova N, Jacobsen W, Niemann CU, et al. Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol 2001; 133: 875.
4. Gourishankar S, Turner P, Halloran P. New developments in immunosuppressive therapy in renal transplantation. Expert Opin Biol Ther 2002; 2: 483.
5. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181.
6. Verbsky JW, Randolph DA, Shornick LP, et al. Nonhematopoietic expression of Janus kinase 3 is required for efficient recruitment of Th2 lymphocytes and eosinophils in OVA-induced airway inflammation. J Immunol 2002; 168: 2475.
7. Verbsky JW, Bach EA, Fang YF, et al. Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells. J Biol Chem 1996; 271: 13976.
8. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 1998; 16: 293.
9. Borie D, Si MS, Morris RE, et al. JAK3 inhibition as a new concept for immune suppression. Curr Opin Investig Drugs 2003; 4: 1297.
10. Kudlacz E, Perry B, Sawyer P, et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4: 51.
11. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875.
12. Borie D, Hausen B, Larson M, et al. A life-supporting technique of renal allotransplantation in Macaca fascicularis to evaluate novel immunosuppressive drugs in nonhuman primates. J Surg Res 2002; 107: 64.
13. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
14. O'Rourke CM, Brammer DW, St Romain G, et al. Calcium carbonate urolithiasis in an adult male cynomolgus monkey. Lab Anim Sci 1995; 45: 222.
15. Pals DT, Orley J. A nonhuman primate model for evaluating the potential of antihypertensive drugs to cause orthostatic hypotension. J Pharmacol Methods 1983; 9: 183.
16. Behbod F, Erwin-Cohen RA, Wang ME, et al. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol 2001; 166: 3724.
17. Stepkowski SM, Erwin-Cohen RA, Behbod F, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002; 99: 680.
18. Li XC, Ima A, Li Y, et al. Blocking the common gamma-chain of cytokine receptors induces T cell apoptosis and long-term islet allograft survival. J Immunol 2000; 164: 1193.
19. O'Shea JJ, Pesu M, Borie DC, et al. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3: 555.
20. Borie DC, O'Shea JJ, Changelian PS. JAK3 inhibition, a viable new modality of immunosuppression. Trends Mol Med 2004; 10: 532.
21. Roodnat JI, van Riemsdijk IC, Mulder PG, et al. The superior results of living-donor renal transplantation are not completely caused by selection or short cold ischemia time: a single-center, multivariate analysis. Transplantation 2003; 75: 2014.
22. Birsan T, Hausen B, Higgins JP, et al. Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 2003; 75: 2106.
23. Hausen B, Klupp J, Christians U, et al. Coadministration of either cyclosporine or steroids with humanized monoclonal antibodies against CD80 and CD86 successfully prolong allograft survival after life supporting renal transplantation in cynomolgus monkeys. Transplantation 2001; 72: 1128.
24. Cullen PR, Lester S, Rouch J, et al. Mixed lymphocyte reaction and graft survival in forty cadaveric renal transplants. Clin Exp Immunol 1977; 28: 218.
25. Jeffery JR, Cheung K, Masniuk J, et al. Mixed lymphocyte culture responses. Lack of correlation with cadaveric renal allograft survival and blood transfusions. Transplantation 1984; 38: 42.
26. Schuurman HJ, Ringers J, Schuler W, et al. Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation. Transplantation 2000; 69: 737.
27. Schuurman HJ, Slingerland W, Mennninger K, et al. Pharmacokinetics of cyclosporine in monkeys after oral and intramuscular administration: relation to efficacy in kidney allografting. Transpl Int 2001; 14: 320.
28. Menninger K, Wieczorek G, Riesen S, et al. The origin of cynomolgus monkey affects the outcome of kidney allografts under Neoral immunosuppression. Transplant Proc 2002; 34: 2887.
29. Baylis C, Corman B. The aging kidney: insights from experimental studies. J Am Soc Nephrol 1998; 9: 699.
30. Segoloni GP, Messina M, Triolo G, et al. Impact of donor age in kidney transplantation. Transplant Proc 1991; 23: 2620.
31. Jurewicz WA. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplant Proc 1999; 31: 64S.
32. Rush D, Nickerson P, Jeffery J. Protocol biopsies in the management of renal allograft recipients. Curr Opin Nephrol Hypertens 2000; 9: 615.
33. Cho CS, Burkly LC, Fechner JH Jr., et al. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. Transplantation 2001; 72: 587.
34. Brommage R, Hotchkiss CE, Lees CJ, et al. Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 1999; 84: 3757.
35. Conklyn M, Andresen C, Changelian P, et al. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing. J Leukoc Biol 2004.
36. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995; 270: 797.
37. Hsieh CL, Obara H, Ogura Y, et al. NK cells and transplantation. Transpl Immunol 2002; 9: 111.
38. Guilbeau JM. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002; 36: 1391.
39. King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75: 1437.
40. Qi S, Xu D, Peng J, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 2000; 69: 1275.
41. McInnes EF, Jarrett RF, Langford G, et al. Posttransplant lymphoproliferative disorder associated with primate gamma-herpesvirus in cynomolgus monkeys used in pig-to-primate renal xenotransplantation and primate renal allotransplantation. Transplantation 2002; 73: 44.
42. Gaschen L, Schuurman HJ. Ultrasound detection of non-Hodgkin's lymphoma in three cynomolgus monkeys after renal transplantation and cyclosporine immunosuppression. J Med Primatol 2001; 30: 88.
43. Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 2002; 73: 1431.
44. Ghanekar A, Lajoie G, Luo Y, et al. Improvement in rejection of human decay accelerating factor transgenic pig-to-primate renal xenografts with administration of rabbit antithymocyte serum. Transplantation 2002; 74: 28.
45. Nickeleit V, Hirsch HH, Binet IF, et al. Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease. J Am Soc Nephrol 1999; 10: 1080.
46. Nickeleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309.
47. Fishman JA. BK virus nephropathy - polyomavirus adding insult to injury. N Engl J Med 2002; 347: 527.
48. van Gorder MA, Della PP, Henson JW, et al. Cynomolgus polyoma virus infection: a new member of the polyoma virus family causes interstitial nephritis, ureteritis, and enteritis in immunosuppressed cynomolgus monkeys. Am J Pathol 1999; 154: 1273.
49. Hutchings A, Wu J, Asiedu C, et al. The immune decision toward allograft tolerance in non-human primates requires early inhibition of innate immunity and induction of immune regulation. Transpl Immunol 2003; 11: 335.
50. Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. 1976. Agents Actions 1994; 43: 179.
51. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. Transplant Proc 1987; 19: 1284.
52. Morris RE, Hoyt EG, Eugui EM, et al. Prolongation of rat heart allograft survival by RS-61443. Surg Forum 1989; 40: 337.
53. Calne RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 2.
54. Morris RE, Meiser B. A new pharmacologic action for an old compound. Med Sci Res 1989; 17: 877.
55. Quesniaux VF, Menninger K, Kunkler A, et al. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD. Transpl Immunol 2000; 8: 177.
56. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323.
57. Collier DS, Calne RY, Pollard SG, et al. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23: 2246.
58. Verlangieri AJ, DePriest JC, Kapeghian JC. Normal serum biochemical, hematological, and EKG parameters in anesthetized adult male Macaca fascicularis and Macaca arctioides. Lab Anim Sci 1985; 35: 63.
59. Paniagua R, Campbell A, Changelian PS, et al. Quantitative analysis of the immunosuppressive CP-690,550 in whole blood by column switching high-performance liquid chromatography with mass spectrometry detection. Ther Drug Mon 2005; in press.